Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius LS01 + bifidobacterium breve B632
- Development stage
- Preclinical
- Lead developer
- Probiotical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus salivarius LS01 (DSM 22775) + Bifidobacterium breve B632 (DSM 24706) is a combination of two live probiotic strains developed by Probiotical. It is also marketed under the brand name BIFIASTHM®. This biologic therapy is designed to act as a microbiome-based immunomodulator. The mechanism of action is believed to involve the gut-lung axis, where it suppresses pro-inflammatory cytokines such as IL-4, IL-13, and TNF-α, while increasing the production of the anti-inflammatory cytokine IL-10 and inhibiting NF-κB activation. Primarily studied for pediatric asthma and wheezing, the combination significantly reduced asthma exacerbations in the PROPAM (Probiotics in Pediatric Asthma Management) clinical trial. It has also shown potential benefits for atopic dermatitis and other allergic conditions. The product is typically administered as an oral powder, with each strain at a concentration of 1 x 10^9 CFU, mixed with bulking agents like maltodextrin.
- Brand names
- BIFIASTHM
- Other names
- Ligilactobacillus salivarius LS01 + Bifidobacterium breve B632
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))NF-κBIL-4 (Interleukin 4)IL10 (Interleukin-10)IL-13 (Interleukin-13)
Beyond the preview
Go deeper on lactobacillus salivarius LS01 + bifidobacterium breve B632.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius LS01 + bifidobacterium breve B632.